Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 Next >
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Annual General Meeting of April 30, 2024
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.